Pharma’s Almanac: Harnessing Macrophage Biology to Overcome Tumor Immune Evasion

In a wide-ranging Q&A with Pharma’s Almanac, Pheast Therapeutics CEO Roy Maute highlights the scientific rationale underlying Pheast’s differentiated approach to targeting macrophage biology and the potential advantages of PHST001 over earlier approaches in the field. Maute discusses encouraging early evidence of biological and clinical activity, the opportunity for PHST001 across multiple tumor types and combinations, and how Pheast’s deep expertise in tumor biology is supporting a broader pipeline of novel oncology medicines, including bispecific ADC PHST677. Read the full article here.